|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Heasman SJ and Ridley AJ: Mammalian Rho
GTPases: new insights into their functions from in vivo studies.
Nat Rev Mol Cell Biol. 9:690–701. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jaffe AB and Hall A: Rho GTPases:
biochemistry and biology. Annu Rev Cell Dev Biol. 21:247–269. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dovas A and Couchman JR: RhoGDI: multiple
functions in the regulation of Rho family GTPase activities.
Biochem J. 390:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Y, Rivera Rosado LA, Moon SY and
Zhang B: Silencing of D4-GDI inhibits growth and invasive behavior
in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK
signaling. J Biol Chem. 284:12956–12965. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moissoglu K, McRoberts KS, Meier JA,
Theodorescu D and Schwartz MA: Rho GDP dissociation inhibitor 2
suppresses metastasis via unconventional regulation of RhoGTPases.
Cancer Res. 69:2838–2844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gildea JJ, Seraj MJ, Oxford G, et al:
RhoGDI2 is an invasion and metastasis suppressor gene in human
cancer. Cancer Res. 62:6418–6423. 2002.PubMed/NCBI
|
|
8
|
Theodorescu D, Sapinoso LM, Conaway MR,
Oxford G, Hampton GM and Frierson HF Jr: Reduced expression of
metastasis suppressor RhoGDI2 is associated with decreased survival
for patients with bladder cancer. Clin Cancer Res. 10:3800–3806.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y and Zhang B: D4-GDI, a Rho GTPase
regulator, promotes breast cancer cell invasiveness. Cancer Res.
66:5592–5598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cho HJ, Baek KE, Park SM, et al: RhoGDI2
expression is associated with tumor growth and malignant
progression of gastric cancer. Clin Cancer Res. 15:2612–2619. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng Z, Li J, He X, et al: Involvement of
RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil.
Hepatogastroenterology. 57:1106–1112. 2010.PubMed/NCBI
|
|
12
|
Wang YW, Qu Y, Li JF, et al: In vitro and
in vivo evidence of metallopanstimulin-1 in gastric cancer
progression and tumorigenicity. Clin Cancer Res. 12:4965–4973.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuen HF, Chan YP, Chan KK, et al: Id-1 and
Id-2 are markers for metastasis and prognosis in oesophageal
squamous cell carcinoma. Br J Cancer. 97:1409–1415. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ben QW, Wang JC, Liu J, et al: Positive
expression of L1-CAM is associated with perineural invasion and
poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol.
17:2213–2221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoshikawa R, Kusunoki M, Yanagi H, et al:
Dual antitumor effects of 5-fluorouracil on the cell cycle in
colorectal carcinoma cells: a novel target mechanism concept for
pharmacokinetic modulating chemotherapy. Cancer Res. 61:1029–1037.
2001.
|
|
16
|
Sinha P, Hütter G, Köttgen E, Dietel M,
Schadendorf D and Lage H: Search for novel proteins involved in the
development of chemoresistance in colorectal cancer and
fibrosarcoma cells in vitro using two-dimensional electrophoresis,
mass spectrometry and microsequencing. Electrophoresis.
20:2961–2969. 1999. View Article : Google Scholar
|
|
17
|
Goto T, Takano M, Sakamoto M, et al: Gene
expression profiles with cDNA microarray reveal RhoGDI as a
predictive marker for paclitaxel resistance in ovarian cancers.
Oncol Rep. 15:1265–1271. 2006.PubMed/NCBI
|
|
18
|
Lee DH, Chung K, Song JA, et al: Proteomic
identification of paclitaxel-resistance associated hnRNP A2 and GDI
2 proteins in human ovarian cancer cells. J Proteome Res.
9:5668–5676. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cho HJ, Baek KE, Park SM, et al: RhoGDI2
confers gastric cancer cells resistance against cisplatin-induced
apoptosis by upregulation of Bcl-2 expression. Cancer Lett.
311:48–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Na S, Chuang TH, Cunningham A, et al:
D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced
apoptosis. J Biol Chem. 271:11209–11213. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Essmann F, Wieder T, Otto A, Müller EC,
Dörken B and Daniel PT: GDP dissociation inhibitor D4-GDI (Rho-GDI
2), but not the homologous rho-GDI 1, is cleaved by caspase-3
during drug-induced apoptosis. Biochem J. 346:777–783. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krieser RJ and Eastman A: Cleavage and
nuclear translocation of the caspase 3 substrate Rho
GDP-dissociation inhibitor, D4-GDI, during apoptosis. Cell Death
Differ. 6:412–419. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi MR, Groot M and Drexler HC:
Functional implications of caspase-mediated RhoGDI2 processing
during apoptosis of HL60 and K562 leukemia cells. Apoptosis.
12:2025–2035. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Wang J, Zhang X, Zeng Y, Liang L and
Ding Y: Overexpression of RhoGDI2 correlates with tumor progression
and poor prognosis in colorectal carcinoma. Ann Surg Oncol.
19:145–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cho HJ, Baek KE, Nam IK, et al: PLCgamma
is required for RhoGDI2-mediated cisplatin resistance in gastric
cancer. Biochem Biophys Res Commun. 414:575–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
